Related Experiment Videos
[Clinical studies with cefmenoxime in the field of pediatrics]
Insights
Cefmenoxime (CMX), a new cephalosporin antibiotic, demonstrated significant clinical effectiveness and a favorable safety profile in pediatric patients. This study found an 80.6% satisfactory response rate with no observed adverse effects, indicating its potential as a valuable treatment option.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and therapeutics
- Clinical microbiology
Context:
- Pediatric infections pose a significant health challenge, necessitating effective and safe antimicrobial agents.
- The emergence of antibiotic resistance requires continuous development of new therapeutic options.
- Cephalosporins are a widely used class of antibiotics in pediatric care.
Purpose:
- To evaluate the clinical efficacy and safety of cefmenoxime (CMX) in pediatric patients.
- To determine the optimal dosage and duration of CMX treatment for various infections.
- To assess the incidence of adverse events and laboratory abnormalities associated with CMX administration.
Summary:
- A study involving 31 pediatric patients with sepsis, respiratory tract infections, and urinary tract infections was conducted.
- Patients received cefmenoxime (CMX) at daily doses ranging from 30 mg/kg to 125 mg/kg, divided into 3 or 4 administrations for 3 to 13 days.
- An overall satisfactory clinical response rate of 80.6% was observed, with 16 excellent and 9 good responses.
- No significant side effects or drug-related laboratory abnormalities were reported during the study.
Impact:
- Cefmenoxime (CMX) shows promise as a safe and effective antibiotic for treating common pediatric infections.
- The findings support the potential integration of CMX into pediatric infectious disease treatment protocols.
- Further research may explore CMX's role in managing more complex or resistant pediatric infections.
Abstract:
The present study was performed to evaluate the clinical effectiveness and safety of cefmenoxime (CMX), a new cephalosporin antibiotic for injection in the field of pediatrics. Thirty-one cases, including 2 cases with sepsis, 18 cases with respiratory tract infections and 7 cases with urinary tract infections, were given CMX at daily doses of 30 mg/kg to 125 mg/kg divided into 3 or 4 for 3 days to 13 days. Clinical responses were excellent in 16 cases, good in 9 cases and poor in 6 cases, the satisfactory response being 80.6%. No side effects and no abnormal laboratory findings relating to the drug were observed.